TGT
25
-24
HSIC
54
-3
DHR
35
3
HSY
34
3
PSA
51
-4
PNW
66
3
CSX
51
-2
SYF
85
2
ZTS
47
2
MTCH
37
7
TXT
48
2
SIG
43
3
STI
47
-12
FMC
31
5
LUV
39
-5
IFF
53
2
BMY
53
-7
LB
34
8
HOG
29
-4
M
20
-4
TGT
25
-24
HSIC
54
-3
DHR
35
3
HSY
34
3
PSA
51
-4
PNW
66
3
CSX
51
-2
SYF
85
2
ZTS
47
2
MTCH
37
7
TXT
48
2
SIG
43
3
STI
47
-12
FMC
31
5
LUV
39
-5
IFF
53
2
BMY
53
-7
LB
34
8
HOG
29
-4
M
20
-4
Financhill
Back

Atara Biotherapeutics 10K Form

Sell
43

ATRA
Atara Biotherapeutics

Last Price:
10.60
Seasonality Move:
16.06%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ATRA News And Ratings

See the #1 stock for the next 7 days that we like better than ATRA

ATRA Financial Statistics

Sales & Book Value

Annual Sales: $8.57M
Cash Flow: $-3.99M
Price / Cash Flow: 0
Annual Sales: $-15.77
Price / Book: 0

Profitability

EPS (TTM): -25.76000
Net Income (TTM): $-133.16M
Gross Margin: $-313K
Return on Equity: 0%
Return on Assets: -85.41%

Atara Biotherapeutics Earnings Forecast

Key Atara Biotherapeutics Financial Ratios

  • The Gross Profit Margin over the past 6 years for ATRA is -3.65%.
  • The Selling, General & Administrative Expenses for ATRA have been equal to 593.82% of Gross Profit Margin.
  • The Research & Development expenses have been 2,622.01% of Revenue.
  • The Interest Expense is -1.91% of Operating Income.
  • The Net Earning history of ATRA is -3,220.88% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 4 years.

Atara Biotherapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ATRA
CUSIP: 046513
Website: atarabio.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0.59
Quick Ratio: 0.44

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ATRA Technical Analysis vs Fundamental Analysis

Sell
43
Atara Biotherapeutics (ATRA) is a Sell

Is Atara Biotherapeutics a Buy or a Sell?